Beneath the conditions of the revised agreement.

Beneath the conditions of the revised agreement, which will go into effect January 1, 2013, Bristol-Myers Squibb shall return to Sanofi its rights to Plavix and Avapro/Avalide in every markets worldwide with the exception of Plavix in the U.S. And Puerto Rico, providing Sanofi single control and freedom to commercially operate http://testosterone-p.com/ . In exchange, Bristol-Myers Squibb will receive royalty obligations on Sanofi’s sales of branded and unbranded Plavix worldwide, excluding the U.S.